319 - Single-Dose and Repeat Single-Dose Ascending Dose Study Evaluating Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intramuscular CD388, a Novel Long-acting Drug-Fc Conjugate for Universal Prevention of Seasonal and Pandemic Influenza

Friday, October 18, 2024

12:30 PM – 12:35 PM US PT

Location: Halls JK - Arena 1

Rapid Fire Presenter(s)

Shawn Flanagan, PhD (he/him/his)

VP, Clinical Pharmacology and Early Development
Cidara Therapeutics
San Diego, CA, United States

Co-Author(s)

OE

Ozlem Equils, MD

Senior Medical Director
Cidara Therapeutics
San Diego, California, United States
RR

Roxana E. Rojas, M.D., Ph.D.

Senior Medical Director
Janssen Research & Development
Brisbane, California, United States
TB

Tristan Baguet, PharmD

Janssen R&D
Steenhuffel, Vlaams-Brabant, Belgium
SW

Sy-Shi Wang, Ph.D.

Janssen Pharmaceutical
Brisbane, California, United States
VO

Voon Ong, Executive Director

Executive Director, Preclinical Development
Cidara Therapeutics
San Diego, California, United States
Taylor Sandison, MD, MPH (he/him/his)

Chief Medical Officer
Cidara Therapeutics
San Diego, CA, United States

Disclosure(s):

Shawn Flanagan, PhD: Cidara Therapeutics: Employee, Salaried Employee, Stocks/Bonds (Public Company), Stocks/Bonds (Public Company)

Ozlem Equils, MD: Cidara Therapeutics: Employee, Stocks/Bonds (Public Company)

Roxana E. Rojas, M.D., Ph.D.: Janssen Research & Development LLC: Employee, Stocks/Bonds (Public Company); Johnson and Johnson: Stocks/Bonds (Public Company)

Tristan Baguet, PharmD: Johnson&johnson: Stocks/Bonds (Public Company)

Sy-Shi Wang, Ph.D.: Janssen Research & Development LLC: Employee, Stocks/Bonds (Public Company)

Voon Ong, Executive Director: Cidara Therapeutics: Stocks/Bonds (Public Company)

Taylor Sandison, MD, MPH: Cidara Therapeutics Inc: Employee, Stocks/Bonds (Public Company)